Esperion Therapeutics (ESPR) Non-Current Debt (2012 - 2026)

Esperion Therapeutics has reported Non-Current Debt for 8 years, with the latest figure at $152.7 million in Q1 2026.

• For the quarter ending Q1 2026, Non-Current Debt rose 7.94% year-over-year to $152.7 million; the trailing twelve-month figure through Mar 2026 stood at $152.7 million (up 7.94% YoY), and the FY2025 full-year result was $152.2 million, up 7.98% from the prior year.
• Non-Current Debt for Q1 2026 stood at $152.7 million, roughly flat from $152.2 million in the prior quarter.
• The five-year high for Non-Current Debt was $152.7 million in Q1 2026, with the low at $141.0 million in Q4 2024.
• Historically, Non-Current Debt has averaged $147.6 million across 3 years, with a median of $149.1 million in 2025.
• Annual changes were most pronounced in 2025 — Non-Current Debt increased 7.98% — and 2026, when it rose 7.94%.
• Esperion Therapeutics' Non-Current Debt stood at $141.0 million in 2024, then advanced by 7.98% to $152.2 million in 2025, then advanced by 0.3% to $152.7 million in 2026.
• The last three Non-Current Debt figures came in at $152.7 million (Q1 2026), $152.2 million (Q4 2025), and $151.7 million (Q3 2025), per Business Quant data.